Evidence map›Paper›PMID 37752164›Full record

ArticleScientific reports2023

Meta-learning for transformer-based prediction of potent compounds.

Hengwei Chen, Jürgen Bajorath

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution.

Hengwei ChenDepartment of Life Science Informatics and Data Science, B-IT, Lamarr Institute for Machine Learning and Artificial Intelligence, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Friedrich-Hirzebruch-Allee 5/6, 53115, Bonn, Germany.
Jürgen BajorathDepartment of Life Science Informatics and Data Science, B-IT, Lamarr Institute for Machine Learning and Artificial Intelligence, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Friedrich-Hirzebruch-Allee 5/6, 53115, Bonn, Germany. bajorath@bit.uni-bonn.de.
Lamarr Institute for Machine Learning and Artificial Intelligence

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For many machine learning applications in drug discovery, only limited amounts of training data are available. This typically applies to compound design and activity prediction and often restricts machine learning, especially deep learning. For low-data applications, specialized learning strategies can be considered to limit required training data. Among these is meta-learning that attempts to enable learning in low-data regimes by combining outputs of different models and utilizing meta-data from these predictions. However, in drug discovery settings, meta-learning is still in its infancy. In this study, we have explored meta-learning for the prediction of potent compounds via generative design using transformer models. For different activity classes, meta-learning models were derived to predict highly potent compounds from weakly potent templates in the presence of varying amounts of fine-tuning data and compared to other transformers developed for this task. Meta-learning consistently led to statistically significant improvements in model performance, in particular, when fine-tuning data were limited. Moreover, meta-learning models generated target compounds with higher potency and larger potency differences between templates and targets than other transformers, indicating their potential for low-data compound design.

Indexed as

Drug DiscoveryElectric Power SuppliesMachine Learning

Identifiers

PMID37752164
PMCPMC10522638
OpenAlexW4387037895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.